From: Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer
Agent | Classification | Targeting epitope | Imaging modality | Imaging window | Notes | Translation stage | Ref |
---|---|---|---|---|---|---|---|
Cy5.5-mATF-IO | ATF-based NP | uPA-binding region | MRI, optical | 24-48 h | Mouse ATF | In vivo preclinical | |
hATF-Cy5.5-IO-Nos | ATF-based NP | uPA-binding region | MRI, optical | n.v.t. | Human ATF | In vitro preclinical | [200] |
ATF-I125 | ATF-based | uPA-binding region | n.a. | n.v.t. | Â | In vitro preclinical | [201] |
NIR-830-mATF-IONP | ATF-based NP | uPA-binding region | PA, optical | 24 h | Mouse ATF | In vivo preclinical | [202] |
ATF-IONP-Gem | ATF-based NP | uPA-binding region | MRI | 48 h | Mouse and human ATF | In vivo preclinical | [203] |
NIR-830-hATF-IONP | ATF-based NP | uPA-binding region | Optical | 24 h | Human ATF | In vivo preclinical | [204] |
NAc-dD-CHA-F-dS-dR-Y-L-W-S-βAla)2-K-K(DOTA)-NH2-111In | Peptide | uPA-binding region | n.a. | n.v.t. |  | In vitro preclinical | [201] |
99mTc-Hynic-PEG-AE105 | Peptide | uPA-binding region | SPECT | 4-6 h |  | In vivo preclinical | [205] |
64Cu-DOTA-AE105 | Peptide | uPA-binding region | PET | 24 h |  | Phase I clinical | |
68Ga-NOTA-AE105 | Peptide | uPA-binding region | PET | 10 min-1 h |  | Phase I clinical | |
ICG-Glu-Glu-AE105 | Peptide | uPA-binding region | Optical | 6-24 h |  | In vivo preclinical | |
CH1055-4Glu-AE105 | Peptide | uPA-binding region | Optical | 72-96 h |  | In vivo preclinical | [210] |
AF680-2G10 | Antibody | uPA-binding region | Optical | 48-96 h | Recombinant antibody with trastuzumab Fc region | In vivo preclinical | |
111ln-2G10 | Antibody | uPA-binding region | SPECT | 48-120 h | Recombinant antibody with trastuzumab Fc region | In vivo preclinical | |
AF680-3C6 | Antibody | β1-binding region | Optical | 48-96 h | Recombinant antibody with trastuzumab Fc region | In vivo preclinical | [211] |
111ln-3C6 | Antibody | β1-binding region | SPECT | 48-96 h | Recombinant antibody with trastuzumab Fc region | In vivo preclinical | [211] |
111In-ZW800-1-ATN-658 (Hybrid ATN-658) | Antibody | Domain 3, amino acids 268-275 | Optical, SPECT | 24-72 h | Mouse antibody | In vivo preclinical |